Sarah A Holstein
Overview
Explore the profile of Sarah A Holstein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
124
Citations
2047
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ayub Ali M, Maalouf M, Feng D, Rashid M, Gehrke N, Chhonker Y, et al.
Bioorg Med Chem
. 2025 Mar;
122:118140.
PMID: 40043324
Geranylgeranyl diphosphate synthase (GGDPS) produces the 20-carbon isoprenoid species used in protein geranylgeranylation reactions. Inhibition of GGDPS has emerged as a novel means of disrupting the activity of geranylgeranylated proteins...
2.
Haney S, Chhonker Y, Rashid M, Murry D, Holstein S
Drug Metab Dispos
. 2025 Mar;
53(3):100038.
PMID: 40024136
Geranylgeranyl diphosphate synthase produces the isoprenoid geranylgeranyl diphosphate, which is used in protein geranylgeranylation. Our previous work illustrates that geranylgeranyl diphosphate synthase inhibitors (GGSIs) disrupt Rab-mediated protein trafficking in cells,...
3.
4.
Muehlebach M, Haney S, Chhonker Y, Rashid M, Murry D, Talmon G, et al.
JBMR Plus
. 2024 Dec;
9(1):ziae133.
PMID: 39697524
Nitrogen bisphosphonates, such as zoledronic acid, target the enzyme farnesyl diphosphate synthase (FDPS) in the isoprenoid biosynthetic pathway (IBP), and are the frontline treatment for osteolytic bone diseases. A strong...
5.
Ellithi M, Elsallab M, Lunning M, Holstein S, Sharma S, Trinh J, et al.
Transplant Cell Ther
. 2024 Dec;
31(2):71.e1-71.e14.
PMID: 39672542
Chimeric antigen receptor T (CAR T) cell therapies have emerged as a valuable treatment modality for patients with plasma cell disorders. As the population of patients receiving CAR T therapies...
6.
Vogl D, Atrash S, Holstein S, Nadeem O, Benson Jr D, Benson D, et al.
Blood
. 2024 Dec;
145(9):944-955.
PMID: 39630057
Interferon alfa has activity against multiple myeloma (MM). Modakafusp alfa is an immunocytokine comprising 2 attenuated interferon alfa-2b molecules and an anti-CD38 immunoglobulin G4 antibody, targeting delivery of interferon alfa...
7.
Voorhees P, Sborov D, Laubach J, Kaufman J, Reeves B, Rodriguez C, et al.
Future Oncol
. 2024 Oct;
21(1):25-49.
PMID: 39452950
No abstract available.
8.
Pant A, Laliwala A, Holstein S, Mohs A
J Control Release
. 2024 Oct;
376:215-230.
PMID: 39384153
Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse...
9.
Aldhafiri W, Chhonker Y, Ahmed N, Singh S, Haney S, Ford J, et al.
Molecules
. 2024 Sep;
29(18).
PMID: 39339419
A rapid, selective, and sensitive liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantitation of MO-OH-Nap tropolone (MO-OH-Nap) in mouse plasma. MO-OH-Nap is...
10.
Chari A, Kaufman J, Laubach J, Sborov D, Reeves B, Rodriguez C, et al.
Blood Cancer J
. 2024 Jul;
14(1):107.
PMID: 38977707
The randomized, phase 2 GRIFFIN study (NCT02874742) evaluated daratumumab plus lenalidomide/bortezomib/dexamethasone (D-RVd) in transplant-eligible newly diagnosed multiple myeloma (NDMM). We present final post hoc analyses (median follow-up, 49.6 months) of...